
Avinger AVGR
Quarterly report 2024-Q3
added 05-16-2026
Avinger General and Administrative Expenses 2011-2026 | AVGR
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Avinger
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.1 M | 14.2 M | 15.6 M | 14.3 M | 16.5 M | 18.4 M | 25.1 M | 40 M | 29.2 M | 18.5 M | 25.8 M | 22.8 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 40 M | 14.1 M | 21.2 M |
Quarterly General and Administrative Expenses Avinger
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.01 M | 3.6 M | 4.37 M | - | 3.38 M | 3.35 M | 3.54 M | - | 3.38 M | 3.33 M | 4.15 M | - | 3.89 M | 3.92 M | 3.94 M | - | 3.46 M | 2.65 M | 4.39 M | - | 4.09 M | 4.09 M | 3.99 M | - | 4.26 M | 4.2 M | 4.26 M | - | 4.93 M | 6.19 M | 9.32 M | - | 9.41 M | 9.46 M | 12.2 M | - | 6.89 M | 6.54 M | 6.36 M | - | 4.58 M | 4.19 M | 4.14 M | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 12.2 M | 2.65 M | 4.95 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
45.8 M | - | - | $ 3.31 B | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
16.5 M | $ 11.15 | -0.45 % | $ 316 M | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
Alphatec Holdings
ATEC
|
499 M | $ 8.22 | -0.24 % | $ 1.23 B | ||
|
Aziyo Biologics
AZYO
|
15.1 M | - | 1.37 % | $ 20.5 M | ||
|
EDAP TMS S.A.
EDAP
|
14.1 M | $ 4.34 | 2.12 % | $ 162 M | ||
|
BioSig Technologies
BSGM
|
67.5 M | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
LivaNova PLC
LIVN
|
549 M | $ 73.09 | -0.84 % | $ 3.99 B | ||
|
LENSAR
LNSR
|
45.2 M | $ 6.08 | 3.4 % | $ 72.7 M | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
Helius Medical Technologies
HSDT
|
23.1 M | $ 2.31 | 0.05 % | $ 50.9 M | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.46 | -3.15 % | $ 28.6 M | ||
|
OrthoPediatrics Corp.
KIDS
|
120 M | $ 18.22 | -1.54 % | $ 427 M | ||
|
Delcath Systems
DCTH
|
43.5 M | $ 11.34 | 0.94 % | $ 406 M | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
IRIDEX Corporation
IRIX
|
7.73 M | $ 1.01 | 1.5 % | $ 17.1 M | ||
|
Profound Medical Corp.
PROF
|
32.1 M | $ 6.9 | -0.36 % | $ 209 M | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
MiMedx Group
MDXG
|
56.5 M | $ 3.66 | -3.43 % | $ 541 M | ||
|
Pulmonx Corporation
LUNG
|
101 M | $ 1.54 | -0.32 % | $ 62.7 M | ||
|
Electromed
ELMD
|
39.3 M | $ 38.7 | 2.35 % | $ 327 M | ||
|
Myomo
MYO
|
14 M | $ 0.92 | 1.56 % | $ 38.5 M | ||
|
Butterfly Network
BFLY
|
39.2 M | $ 4.45 | 1.14 % | $ 1.1 B | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
1.11 M | - | -0.97 % | $ 54.4 M | ||
|
Sintx Technologies
SINT
|
6.2 M | $ 2.14 | -3.32 % | $ 5.94 M | ||
|
Orthofix Medical
OFIX
|
554 M | $ 10.35 | -14.81 % | $ 410 M | ||
|
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | ||
|
Globus Medical
GMED
|
1.18 B | $ 84.19 | 0.21 % | $ 11.4 B | ||
|
Insulet Corporation
PODD
|
1.16 B | $ 154.41 | -1.39 % | $ 10.9 B | ||
|
TransMedics Group
TMDX
|
185 M | $ 67.16 | -1.24 % | $ 2.28 B | ||
|
CONMED Corporation
CNMD
|
132 M | $ 36.3 | -1.96 % | $ 1.13 B | ||
|
Inspire Medical Systems
INSP
|
625 M | $ 43.77 | -0.86 % | $ 1.29 B | ||
|
Integer Holdings Corporation
ITGR
|
212 M | $ 89.58 | -2.02 % | $ 3.11 B | ||
|
Invacare Corporation
IVC
|
227 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
2.09 B | $ 82.51 | -0.58 % | $ 48.3 B |